These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27467204)

  • 1. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
    Mendes D; Alves C; Batel Marques F
    Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
    McNaughton R; Huet G; Shakir S
    BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
    Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012.
    Bouvy JC; Huinink L; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1004-14. PubMed ID: 27146035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems.
    Aronson JK
    Therapie; 2017 Oct; 72(5):555-561. PubMed ID: 28461037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Br J Clin Pharmacol; 2015 Oct; 80(4):716-26. PubMed ID: 25808713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
    Craveiro NS; Lopes BS; Tomás L; Almeida SF
    Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety: withdrawn medications are only part of the picture.
    Rawson NS
    BMC Med; 2016 Feb; 14():28. PubMed ID: 26873482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.
    Pane J; Coloma PM; Verhamme KM; Sturkenboom MC; Rebollo I
    Drug Saf; 2017 Jan; 40(1):37-47. PubMed ID: 27928726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof-of-Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action.
    Lane S; Lynn E; Shakir S
    Pharmacoepidemiol Drug Saf; 2024 Sep; 33(9):e70003. PubMed ID: 39212104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
    Lane S; Lynn E; Shakir S
    BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.